Drug Profile
Research programme: breast cancer therapeutics - imMAGE Biotherapeutics
Alternative Names: DNA based Vaccine/Anti-CTL4 - Immage Biotehrapeutics; DNA based Vaccine/Anti-PD-L1 - Immage Biotehrapeutics; IMT 001Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Immage Biotherapeutics
- Class Antineoplastics; Cancer vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in USA (Parenteral)
- 28 Nov 2016 ImMAGE Biotherapeutics announces intention to submit IND to US FDA in 2017
- 28 Sep 2016 Immage Biotherapeutics in-licenses SMARTmid™ vectors technology from PepVax before September 2016 (Immage Therapeutics pipeline, September 2016)